Page last updated: 2024-10-28

lidocaine and ER-Negative PR-Negative HER2-Negative Breast Cancer

lidocaine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Chen, JL1
Liu, ST1
Huang, SM1
Wu, ZF1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Long-term Outcomes of Breast Cancer Patients Receiving Levobupivacaine Wound Infiltration or Diclofenac for Postoperative Pain Relief[NCT05829707]Phase 4120 participants (Actual)Interventional2009-01-05Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

1 other study available for lidocaine and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
Apoptosis, Proliferation, and Autophagy Are Involved in Local Anesthetic-Induced Cytotoxicity of Human Breast Cancer Cells.
    International journal of molecular sciences, 2022, Dec-07, Volume: 23, Issue:24

    Topics: Anesthetics, Local; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Female;

2022